Deciphera Pharmaceuticals, Inc. (DCPH): Price and Financial Metrics
GET POWR RATINGS... FREE!
DCPH POWR Grades
- Growth is the dimension where DCPH ranks best; there it ranks ahead of 91.6% of US stocks.
- DCPH's strongest trending metric is Quality; it's been moving down over the last 177 days.
- DCPH ranks lowest in Momentum; there it ranks in the 5th percentile.
DCPH Stock Summary
- Of note is the ratio of DECIPHERA PHARMACEUTICALS INC's sales and general administrative expense to its total operating expenses; merely 17.78% of US stocks have a lower such ratio.
- For DCPH, its debt to operating expenses ratio is greater than that reported by only 14.57% of US equities we're observing.
- With a price/sales ratio of 9.97, DECIPHERA PHARMACEUTICALS INC has a higher such ratio than 88.26% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to DECIPHERA PHARMACEUTICALS INC are YMAB, STRO, FUSN, MRKR, and DTIL.
- Visit DCPH's SEC page to see the company's official filings. To visit the company's web site, go to www.deciphera.com.
DCPH Valuation Summary
- In comparison to the median Healthcare stock, DCPH's price/sales ratio is 100% higher, now standing at 10.2.
- Over the past 65 months, DCPH's EV/EBIT ratio has gone up 8.3.
Below are key valuation metrics over time for DCPH.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| DCPH | 2023-01-20 | 10.2 | 3.3 | -5.6 | -5.4 |
| DCPH | 2023-01-19 | 10.4 | 3.4 | -5.7 | -5.5 |
| DCPH | 2023-01-18 | 11.4 | 3.7 | -6.3 | -6.1 |
| DCPH | 2023-01-17 | 11.8 | 3.8 | -6.5 | -6.3 |
| DCPH | 2023-01-13 | 11.9 | 3.9 | -6.6 | -6.3 |
| DCPH | 2023-01-12 | 12.3 | 4.0 | -6.7 | -6.5 |
DCPH's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- DCPH has a Quality Grade of D, ranking ahead of 19.93% of graded US stocks.
- DCPH's asset turnover comes in at 0.137 -- ranking 232nd of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows DCPH's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.137 | 0.980 | -0.586 |
| 2021-03-31 | 0.104 | 0.993 | -0.553 |
| 2020-12-31 | 0.062 | 0.995 | -0.544 |
| 2020-09-30 | 0.033 | 0.996 | -0.556 |
| 2020-06-30 | 0.011 | 0.999 | -0.565 |
| 2020-03-31 | 0.044 | 1.000 | -0.565 |
DCPH Price Target
For more insight on analysts targets of DCPH, see our DCPH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $68.50 | Average Broker Recommendation | 1.36 (Strong Buy) |
DCPH Stock Price Chart Interactive Chart >
DCPH Price/Volume Stats
| Current price | $17.31 | 52-week high | $22.76 |
| Prev. close | $17.98 | 52-week low | $6.51 |
| Day low | $17.22 | Volume | 477,100 |
| Day high | $18.08 | Avg. volume | 1,183,228 |
| 50-day MA | $17.02 | Dividend yield | N/A |
| 200-day MA | $14.98 | Market Cap | 1.17B |
Deciphera Pharmaceuticals, Inc. (DCPH) Company Bio
Deciphera Pharmaceuticals LLC develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. Its product pipeline includes Altiratinib (DCC-2701), a MET/TIE2/VEGFR2/TRK kinase inhibitor; DCC-2618, a pan-KIT inhibitor; Rebastinib, a TIE2/VEGFR1 kinase inhibitor; and LY3009120 (DP-4978), a pan-RAF inhibitor. The company was founded in 2003 and is based in Waltham, Massachusetts.
Latest DCPH News From Around the Web
Below are the latest news stories about DECIPHERA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate DCPH as an investment opportunity.
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesWALTHAM, Mass., January 24, 2023--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the closing of its underwritten public offering of 7,986,111 shares of its common stock. The shares of common stock sold include 1,041,666 shares pursuant to the option granted by Deciphera to the underwriters, which option was exercised in full. The |
Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series SessionWALTHAM, Mass., January 24, 2023--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the presentation of additional data from the planned exploratory analysis from the INTRIGUE Phase 3 clinical study of QINLOCK® using circulating tumor DNA (ctDNA) from patients with gastrointestinal stromal tumor (GIST) previously treated with imatin |
Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common StockWALTHAM, Mass., January 20, 2023--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the pricing of an underwritten public offering of 6,944,445 shares of its common stock at a public offering price of $18.00 per share. The aggregate gross proceeds to Deciphera from this offering are expected to be approximately $125 million, before |
Deciphera Pharmaceuticals Announces Proposed Public Offering of Common StockWALTHAM, Mass., January 18, 2023--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it intends to offer and sell $125,000,000 of shares of its common stock in an underwritten public offering. In addition, Deciphera intends to grant the underwriters a 30-day option to purchase up to an additional $18,750,000 of shares of common |
Deciphera (DCPH) Rises 70% in the Past 6 Months: Here's WhyDeciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. The recent restructuring initiative is saving costs. |
DCPH Price Returns
| 1-mo | 5.61% |
| 3-mo | 2.85% |
| 6-mo | 27.56% |
| 1-year | 122.49% |
| 3-year | 10.55% |
| 5-year | 166.31% |
| YTD | 5.61% |
| 2022 | 67.76% |
| 2021 | -31.52% |
| 2020 | -8.31% |
| 2019 | 196.52% |
| 2018 | -7.41% |
Continue Researching DCPH
Want to see what other sources are saying about Deciphera Pharmaceuticals Inc's financials and stock price? Try the links below:Deciphera Pharmaceuticals Inc (DCPH) Stock Price | Nasdaq
Deciphera Pharmaceuticals Inc (DCPH) Stock Quote, History and News - Yahoo Finance
Deciphera Pharmaceuticals Inc (DCPH) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...